Edition:
United Kingdom

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

10,645JPY
25 Sep 2018
Change (% chg)

¥375 (+3.65%)
Prev Close
¥10,270
Open
¥10,395
Day's High
¥10,695
Day's Low
¥10,355
Volume
1,308,300
Avg. Vol
1,428,885
52-wk High
¥11,490
52-wk Low
¥5,402

Latest Key Developments (Source: Significant Developments)

Eisai And Merck Announce China NMPA Approval Of Lenvima For Treatment Of Unresectable HCC
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND MERCK ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA® (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC).MERCK & CO INC - APPROVAL WAS BASED ON RESULTS FROM REFLECT STUDY (STUDY 304), AN OPEN-LABEL, PHASE 3 TRIAL.  Full Article

Morphotek Announces FDA Acceptance Of IND For Cancer Treatment
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Eisai Co Ltd <4523.T>::MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202.MORPHOTEK - U.S. FDA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION FOR MORAB-202.  Full Article

Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Biogen Inc :Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab.Biogen Inc - ‍Eisai has exercised its option to jointly develop and commercialize aducanumab, with Biogen continuing as development lead​.Biogen Inc - Co, Eisai to co-promote co's multiple sclerosis treatments, avonex , tysabri, tecfidera in Japan to accounts that co does not call upon​.Biogen Inc - ‍Neither party is making any upfront payments associated with exercise of aducanumab option​.Biogen Inc - ‍Under terms of agreement co will receive 55 percent of potential profits in United States and 68.5 percent of potential profits in Europe​.Biogen Inc - ‍Eisai's, Biogen's respective milestone payments under original agreement for aducanumab and BAN2401, have been eliminated​.Biogen Inc - ‍ Companies will continue to jointly develop elenbecestat (e2609), a beta amyloid cleaving enzyme (bace) inhibitor, and BAN2401​.Biogen Inc - ‍Financial terms for elenbecestat and ban2401 remain unchanged, other than eliminated BAN2401 milestone payments​.Biogen - Co to continue to lead phase 3 development of aducanumab, remain solely responsible for development costs for aducanumab until April 2018​.Biogen Inc - ‍ Under terms of agreement Eisai will receive 80 percent of potential profits in Japan and Asia excluding China and South Korea​.  Full Article

Nikkei rises to 2-week high on weak yen, pharmaceuticals

* Paper sector pushed up by brokerage's target price hike on co